Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416

Yuta Yoshizawa, Ken Ichi Ogawara, Aya Fushimi, Shigeki Abe, Keisuke Ishikawa, Tomoya Araki, Grietje Molema, Toshikiro Kimura, Kazutaka Higaki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The recently emerged concept of "vessel normalization" implies that judicious blockade of vascular endothelial growth factor (VEGF) signaling may transiently "normalize" the tumor vasculature, making it more suitable for tumor disposition of subsequently administered drugs. In this study, therefore, the effect of pretreatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in vivo antitumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated in Colon-26 solid tumor-bearing mice. To improve the solubility and in vivo disposition characteristics of SU5416, the inhibitor was formulated in PEGylated O/W emulsion (PE-SU5416). Pretreatment with PE-SU5416 significantly enhanced the in vivo antitumor effect of PL-PTX, although PE-SU5416 administration alone did not show any antitumor effect. Immunostaining for endothelial cells and pericytes demonstrated that the pretreatment with PE-SU5416 enhanced the pericyte coverage of the tumor vasculature. In addition, tumors treated with PE-SU5416 contained significantly smaller hypoxic regions compared with the nontreated control group, demonstrating that structural normalization of the tumor vasculature resulted in an improvement in tumor vessel functions, including oxygen supply. Furthermore, the pretreatment with PE-SU5416 increased the distribution of PEG liposomes and included PTX in the core region of the tumor, as well as conversely decreasing the ratio of their peripheral distribution. These results suggest that the structural and functional normalization of the tumor vasculature by the pretreatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent antitumor activity of PL-PTX.

Original languageEnglish
Pages (from-to)3486-3494
Number of pages9
JournalMolecular Pharmaceutics
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 3 2012

Fingerprint

Angiogenesis Inhibitors
Paclitaxel
Neoplasms
Pericytes
Liposomes
Semaxinib
Vascular Endothelial Growth Factor Receptor-2
Emulsions
Solubility
Vascular Endothelial Growth Factor A
Colon
Endothelial Cells
Oxygen

Keywords

  • angiogenesis
  • drug delivery
  • paclitaxel
  • PEG liposome
  • VEGF

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Drug Discovery

Cite this

Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. / Yoshizawa, Yuta; Ogawara, Ken Ichi; Fushimi, Aya; Abe, Shigeki; Ishikawa, Keisuke; Araki, Tomoya; Molema, Grietje; Kimura, Toshikiro; Higaki, Kazutaka.

In: Molecular Pharmaceutics, Vol. 9, No. 12, 03.12.2012, p. 3486-3494.

Research output: Contribution to journalArticle

Yoshizawa, Yuta ; Ogawara, Ken Ichi ; Fushimi, Aya ; Abe, Shigeki ; Ishikawa, Keisuke ; Araki, Tomoya ; Molema, Grietje ; Kimura, Toshikiro ; Higaki, Kazutaka. / Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. In: Molecular Pharmaceutics. 2012 ; Vol. 9, No. 12. pp. 3486-3494.
@article{c820fefc8a61460d85449159fbb5cfd5,
title = "Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416",
abstract = "The recently emerged concept of {"}vessel normalization{"} implies that judicious blockade of vascular endothelial growth factor (VEGF) signaling may transiently {"}normalize{"} the tumor vasculature, making it more suitable for tumor disposition of subsequently administered drugs. In this study, therefore, the effect of pretreatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in vivo antitumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated in Colon-26 solid tumor-bearing mice. To improve the solubility and in vivo disposition characteristics of SU5416, the inhibitor was formulated in PEGylated O/W emulsion (PE-SU5416). Pretreatment with PE-SU5416 significantly enhanced the in vivo antitumor effect of PL-PTX, although PE-SU5416 administration alone did not show any antitumor effect. Immunostaining for endothelial cells and pericytes demonstrated that the pretreatment with PE-SU5416 enhanced the pericyte coverage of the tumor vasculature. In addition, tumors treated with PE-SU5416 contained significantly smaller hypoxic regions compared with the nontreated control group, demonstrating that structural normalization of the tumor vasculature resulted in an improvement in tumor vessel functions, including oxygen supply. Furthermore, the pretreatment with PE-SU5416 increased the distribution of PEG liposomes and included PTX in the core region of the tumor, as well as conversely decreasing the ratio of their peripheral distribution. These results suggest that the structural and functional normalization of the tumor vasculature by the pretreatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent antitumor activity of PL-PTX.",
keywords = "angiogenesis, drug delivery, paclitaxel, PEG liposome, VEGF",
author = "Yuta Yoshizawa and Ogawara, {Ken Ichi} and Aya Fushimi and Shigeki Abe and Keisuke Ishikawa and Tomoya Araki and Grietje Molema and Toshikiro Kimura and Kazutaka Higaki",
year = "2012",
month = "12",
day = "3",
doi = "10.1021/mp300318q",
language = "English",
volume = "9",
pages = "3486--3494",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416

AU - Yoshizawa, Yuta

AU - Ogawara, Ken Ichi

AU - Fushimi, Aya

AU - Abe, Shigeki

AU - Ishikawa, Keisuke

AU - Araki, Tomoya

AU - Molema, Grietje

AU - Kimura, Toshikiro

AU - Higaki, Kazutaka

PY - 2012/12/3

Y1 - 2012/12/3

N2 - The recently emerged concept of "vessel normalization" implies that judicious blockade of vascular endothelial growth factor (VEGF) signaling may transiently "normalize" the tumor vasculature, making it more suitable for tumor disposition of subsequently administered drugs. In this study, therefore, the effect of pretreatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in vivo antitumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated in Colon-26 solid tumor-bearing mice. To improve the solubility and in vivo disposition characteristics of SU5416, the inhibitor was formulated in PEGylated O/W emulsion (PE-SU5416). Pretreatment with PE-SU5416 significantly enhanced the in vivo antitumor effect of PL-PTX, although PE-SU5416 administration alone did not show any antitumor effect. Immunostaining for endothelial cells and pericytes demonstrated that the pretreatment with PE-SU5416 enhanced the pericyte coverage of the tumor vasculature. In addition, tumors treated with PE-SU5416 contained significantly smaller hypoxic regions compared with the nontreated control group, demonstrating that structural normalization of the tumor vasculature resulted in an improvement in tumor vessel functions, including oxygen supply. Furthermore, the pretreatment with PE-SU5416 increased the distribution of PEG liposomes and included PTX in the core region of the tumor, as well as conversely decreasing the ratio of their peripheral distribution. These results suggest that the structural and functional normalization of the tumor vasculature by the pretreatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent antitumor activity of PL-PTX.

AB - The recently emerged concept of "vessel normalization" implies that judicious blockade of vascular endothelial growth factor (VEGF) signaling may transiently "normalize" the tumor vasculature, making it more suitable for tumor disposition of subsequently administered drugs. In this study, therefore, the effect of pretreatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in vivo antitumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated in Colon-26 solid tumor-bearing mice. To improve the solubility and in vivo disposition characteristics of SU5416, the inhibitor was formulated in PEGylated O/W emulsion (PE-SU5416). Pretreatment with PE-SU5416 significantly enhanced the in vivo antitumor effect of PL-PTX, although PE-SU5416 administration alone did not show any antitumor effect. Immunostaining for endothelial cells and pericytes demonstrated that the pretreatment with PE-SU5416 enhanced the pericyte coverage of the tumor vasculature. In addition, tumors treated with PE-SU5416 contained significantly smaller hypoxic regions compared with the nontreated control group, demonstrating that structural normalization of the tumor vasculature resulted in an improvement in tumor vessel functions, including oxygen supply. Furthermore, the pretreatment with PE-SU5416 increased the distribution of PEG liposomes and included PTX in the core region of the tumor, as well as conversely decreasing the ratio of their peripheral distribution. These results suggest that the structural and functional normalization of the tumor vasculature by the pretreatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent antitumor activity of PL-PTX.

KW - angiogenesis

KW - drug delivery

KW - paclitaxel

KW - PEG liposome

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84870530607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870530607&partnerID=8YFLogxK

U2 - 10.1021/mp300318q

DO - 10.1021/mp300318q

M3 - Article

VL - 9

SP - 3486

EP - 3494

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 12

ER -